CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and can afford the risks. Trading CFDs is high risk and is not suitable for everyone. Refer to our PDS and Target Market Determination. AFSL 513393
Open platformOpen platform

Inovio tumbles on $75 mln stock sale for rare throat disease drug

By Reuters News

** Shares of Inovio Pharmaceuticals INO.O tumble 20% to $1.16 in premarket trading on Fri after $75 mln follow-on priced

** INO late Thurs sold ~71.4 mln shares, including pre-funded warrants, at $1.05

** Offering priced at 27.6% discount to stock's last sale of $1.45

** On Mon, INO shares more than tripled to finish at $1.89 after the US FDA approved co's rare throat disease treatment, branded as Voceryq

** INO intends to use net offering proceeds to fund commercial launch of Voceryq, for development of its clinical pipeline among other purposes, per the prospectus

** Jefferies and Piper Sandler joint bookrunners

** Plymouth Meeting, Pennsylvania-based INO has ~110.2 mln shares outstanding as of Sept 30

** All three analysts covering the stock are bullish and their PTs are $3, $5 and $8, per LSEG data

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.